Retinitis Pigmentosa — Deal Benchmarks & Valuation
Market Analysis
Retinitis Pigmentosa is one of the most actively transacted indications in ophthalmology licensing. Phase 1 deals for retinitis pigmentosa carry a median total deal value of $2.3B, with upfront payments ranging from $150M to $520M. The recommended deal structure allocates approximately 14% to upfront payments and 86% to milestones.
Milestone structures for retinitis pigmentosa deals allocate $630M to development milestones, $551M to regulatory milestones, and $788M to commercial milestones. Royalty rates range from 8.4% to 16.8% at the base tier, with tiered escalation reaching 12.4%-20.8% on peak sales.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What are typical deal terms for retinitis pigmentosa licensing?
What royalty rates are standard for retinitis pigmentosa deals?
How are retinitis pigmentosa deal milestones structured?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.